No connection

Search Results

Corporate Score 35 Bullish

Hemab Therapeutics Files for $212 Million US IPO with Novo Nordisk Foundation Backing

Apr 27, 2026 11:25 UTC
Hemab Therapeutics
Short term

Clinical-stage biotech firm Hemab Therapeutics aims to raise up to $212 million through a public offering of 11.8 million shares. The Cambridge-based company could reach a valuation of approximately $705.7 million.

  • Targeting a raise of up to $212 million
  • Price range set at $16 to $18 per share
  • 11.8 million shares available in the offering
  • Estimated valuation of $705.7 million at the top of the range
  • Strategic investment from Novo Nordisk Foundation

Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, has officially filed with the US Securities and Exchange Commission to launch an initial public offering. The firm is seeking to raise as much as $212 million to support its ongoing operations and development pipeline. Based in Cambridge, Massachusetts, Hemab is notably supported by the Novo Nordisk Foundation, which stands as one of its largest investors. This institutional backing provides a significant foundation for the company as it seeks to transition into the public equity markets. The offering consists of 11.8 million shares, with a proposed price range of $16 to $18 per share. If the offering is priced at the upper end of this range, Hemab's total market valuation would be approximately $705.7 million, according to the outstanding shares listed in the filing. This move reflects a continued appetite for specialized biotech ventures with strong institutional ties. The capital raised will likely be utilized to advance the company's clinical trials and therapeutic research.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 35 Bullish

Apple Expected to Maintain Buyback Focus Amid Anticipated Dividend Hike

Apr 27, 14:12

Score 62 Bullish

Apple Secures Unprecedented March Quarter Global Smartphone Leadership

Apr 27, 14:11

Score 55

Carlyle and QIA Fund BASF Coatings Acquisition via $2 Billion Debt Sale

Apr 27, 14:03

Score 25 Bullish

Upcoming Dividend Run For PTA?

Apr 27, 13:55

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile